RVNC - Revance Therapeutics Stock Price, News & Analysis

$26.05 1.50 (6.11 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$24.55
Today's Range$24.70 - $26.75
52-Week Range$15.85 - $28.75
Volume466,146 shs
Average Volume178,690 shs
Market Capitalization$805.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:RVNC
  • CUSIP: N/A
  • Web: www.revance.com
Debt:
  • Current Ratio: 7.28%
  • Quick Ratio: 7.28%
Sales & Book Value:
  • Annual Sales: $300,000.00
  • Price / Sales: 2,685.76
  • Book Value: $4.59 per share
  • Price / Book: 5.68
Profitability:
  • Trailing EPS: ($3.81)
  • Net Income: $-89,270,000.00
  • Net Margins: -37,161.00%
  • Return on Equity: -67.85%
  • Return on Assets: -57.91%
Misc:
  • Employees: 106
  • Outstanding Shares: 30,930,000
 

Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.95) by $0.06. The biopharmaceutical company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm's revenue was up .0% on a year-over-year basis. During the same period last year, the company earned ($0.64) earnings per share. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

5 equities research analysts have issued twelve-month target prices for Revance Therapeutics' shares. Their predictions range from $28.00 to $50.00. On average, they expect Revance Therapeutics' stock price to reach $37.00 in the next twelve months. View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "RT002 injectable has the potential to be a longer lasting, safe alternative to the current products on the market, including the market leader, Botox. If RVNC can successfully develop RT002, we continue to expect the company could be in a position to submit a BLA in 2019, with a potential approval and launch in 2019/2020." (10/24/2017)
  • 2. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/11/2017)

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:

  • Angus Charles Russell, Independent Chairman of the Board (Age 61)
  • L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director (Age 55)
  • Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer (Age 58)
  • Abhay Joshi Ph.D., Chief Operating Officer (Age 54)
  • Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics (Age 45)
  • Mark J. Foley, Director (Age 51)
  • Robert F. Byrnes, Independent Director (Age 72)
  • Julian S. Gangolli, Independent Director (Age 59)
  • Phyllis I. Gardner M.D., Independent Director (Age 65)
  • Philip J. Vickers, Independent Director (Age 56)

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (11.47%), Bank of New York Mellon Corp (6.50%), Candriam Luxembourg S.C.A. (0.44%), Schwab Charles Investment Management Inc. (0.38%), Essex Investment Management Co. LLC (0.34%) and Principal Financial Group Inc. (0.25%). Company insiders that own Revance Therapeutics stock include Curtis Ruegg, L Daniel Browne, Lauren P Silvernail and Mark J Foley. View Institutional Ownership Trends for Revance Therapeutics.

Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?

Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Bank of New York Mellon Corp, Granite Investment Partners LLC, Essex Investment Management Co. LLC, Suffolk Capital Management LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A. and Principal Financial Group Inc.. Company insiders that have sold Revance Therapeutics company stock in the last year include L Daniel Browne and Lauren P Silvernail. View Insider Buying and Selling for Revance Therapeutics.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, EAM Investors LLC, Schwab Charles Investment Management Inc., SG Americas Securities LLC, Alps Advisors Inc. and Swiss National Bank. View Insider Buying and Selling for Revance Therapeutics.

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of Revance Therapeutics stock can currently be purchased for approximately $26.05.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $805.85 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-89,270,000.00 in net income (profit) each year or ($3.81) on an earnings per share basis. Revance Therapeutics employs 106 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 Gateway Blvd, NEWARK, CA 94560-1152, United States. The biopharmaceutical company can be reached via phone at +1-510-7423400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (RVNC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Revance Therapeutics (NASDAQ:RVNC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.00 (42.03% upside)

Consensus Price Target History for Revance Therapeutics (NASDAQ:RVNC)

Price Target History for Revance Therapeutics (NASDAQ:RVNC)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/AView Rating Details
11/16/2017MizuhoInitiated CoverageBuy -> Buy$37.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00N/AView Rating Details
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$34.00MediumView Rating Details
6/8/2017AegisReiterated RatingBuy$36.00MediumView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00N/AView Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Revance Therapeutics (NASDAQ:RVNC)

Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Earnings History by Quarter for Revance Therapeutics (NASDAQ RVNC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.95)($1.01)$0.05 million$0.08 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.93)($0.90)$0.05 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.85)($0.80)($0.83)
Q2 20172($0.99)($0.98)($0.99)
Q3 20172($1.02)($1.02)($1.02)
Q4 20172($0.99)($0.95)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ RVNC)

Insider Ownership Percentage: 18.86%
Institutional Ownership Percentage: 89.14%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Insider Trades by Quarter for Revance Therapeutics (NASDAQ RVNC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/7/2017Lauren P SilvernailCFOSell10,000$26.83$268,300.00View SEC Filing  
11/7/2017Mark J FoleyDirectorBuy20,000$26.96$539,200.00View SEC Filing  
10/18/2017L Daniel BrowneCEOSell7,662$26.16$200,437.92View SEC Filing  
10/12/2017Lauren P SilvernailCFOSell11,164$26.67$297,743.88View SEC Filing  
9/20/2017L Daniel BrowneCEOSell7,600$23.58$179,208.00View SEC Filing  
8/23/2017L Daniel BrowneCEOSell22,800$22.76$518,928.00View SEC Filing  
5/24/2017L Daniel BrowneCEOSell19,713$20.35$401,159.55View SEC Filing  
5/22/2017L Daniel BrowneCEOSell12,287$20.20$248,197.40View SEC Filing  
5/22/2017Lauren P SilvernailCFOSell1,793$20.20$36,218.60View SEC Filing  
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Revance Therapeutics (NASDAQ RVNC)

Source:
DateHeadline
Revance Therapeutics, Inc. (RVNC) Receives Average Rating of "Buy" from AnalystsRevance Therapeutics, Inc. (RVNC) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 22 at 1:34 AM
Revance Therapeutics (RVNC) Confirms Orphan Drug Designation of RT002 for the Treatment of Cervical DystoniaRevance Therapeutics (RVNC) Confirms Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia
www.streetinsider.com - November 21 at 2:38 AM
Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical DystoniaRevance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia
finance.yahoo.com - November 20 at 4:35 PM
Cantor Fitzgerald Analysts Give Revance Therapeutics, Inc. (RVNC) a $50.00 Price TargetCantor Fitzgerald Analysts Give Revance Therapeutics, Inc. (RVNC) a $50.00 Price Target
www.americanbankingnews.com - November 18 at 12:52 PM
Revance Therapeutics, Inc. (RVNC) Coverage Initiated at MizuhoRevance Therapeutics, Inc. (RVNC) Coverage Initiated at Mizuho
www.americanbankingnews.com - November 16 at 7:47 PM
ETFs with exposure to Revance Therapeutics, Inc. : November 13, 2017ETFs with exposure to Revance Therapeutics, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 7:29 AM
Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : November 10, 2017Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : November 10, 2017
finance.yahoo.com - November 12 at 12:35 PM
Insider Selling: Revance Therapeutics, Inc. (RVNC) CFO Sells 10,000 Shares of StockInsider Selling: Revance Therapeutics, Inc. (RVNC) CFO Sells 10,000 Shares of Stock
www.americanbankingnews.com - November 10 at 12:20 AM
Insider Buying: Revance Therapeutics, Inc. (RVNC) Director Acquires 20,000 Shares of StockInsider Buying: Revance Therapeutics, Inc. (RVNC) Director Acquires 20,000 Shares of Stock
www.americanbankingnews.com - November 10 at 12:20 AM
 Analysts Anticipate Revance Therapeutics, Inc. (RVNC) Will Announce Quarterly Sales of $80,000.00 Analysts Anticipate Revance Therapeutics, Inc. (RVNC) Will Announce Quarterly Sales of $80,000.00
www.americanbankingnews.com - November 9 at 1:06 PM
FY2017 EPS Estimates for Revance Therapeutics, Inc. (RVNC) Reduced by AnalystFY2017 EPS Estimates for Revance Therapeutics, Inc. (RVNC) Reduced by Analyst
www.americanbankingnews.com - November 8 at 11:04 AM
 Brokerages Anticipate Revance Therapeutics, Inc. (RVNC) to Post -$0.94 EPS Brokerages Anticipate Revance Therapeutics, Inc. (RVNC) to Post -$0.94 EPS
www.americanbankingnews.com - November 7 at 5:32 AM
Revance Therapeutics, Inc. to Host Earnings CallRevance Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 12:52 PM
Revance Releases Third Quarter 2017 ResultsRevance Releases Third Quarter 2017 Results
finance.yahoo.com - November 4 at 12:52 PM
Revance reports 3Q lossRevance reports 3Q loss
finance.yahoo.com - November 4 at 12:52 PM
Edited Transcript of RVNC earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of RVNC earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 12:52 PM
Revance Therapeutics, Inc. (RVNC) Releases Quarterly  Earnings Results, Misses Estimates By $0.06 EPSRevance Therapeutics, Inc. (RVNC) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - November 3 at 12:28 AM
ETFs with exposure to Revance Therapeutics, Inc. : October 31, 2017ETFs with exposure to Revance Therapeutics, Inc. : October 31, 2017
finance.yahoo.com - November 1 at 8:17 AM
Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : October 31, 2017Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : October 31, 2017
finance.yahoo.com - November 1 at 8:17 AM
Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : October 30, 2017Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : October 30, 2017
finance.yahoo.com - October 31 at 8:55 AM
Revance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Buy" from AnalystsRevance Therapeutics, Inc. (RVNC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 28 at 2:06 AM
Revance Therapeutics, Inc. (RVNC) CEO Sells $200,437.92 in StockRevance Therapeutics, Inc. (RVNC) CEO Sells $200,437.92 in Stock
www.americanbankingnews.com - October 20 at 10:32 PM
Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar FasciitisRevance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
finance.yahoo.com - October 19 at 8:22 AM
ETFs with exposure to Revance Therapeutics, Inc. : October 18, 2017ETFs with exposure to Revance Therapeutics, Inc. : October 18, 2017
finance.yahoo.com - October 19 at 8:22 AM
Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
finance.yahoo.com - October 19 at 8:22 AM
-$0.94 Earnings Per Share Expected for Revance Therapeutics, Inc. (RVNC) This Quarter-$0.94 Earnings Per Share Expected for Revance Therapeutics, Inc. (RVNC) This Quarter
www.americanbankingnews.com - October 18 at 2:24 PM
Contrasting Revance Therapeutics (RVNC) & Edge Therapeutics (EDGE)Contrasting Revance Therapeutics (RVNC) & Edge Therapeutics (EDGE)
www.americanbankingnews.com - October 17 at 10:52 AM
Revance Therapeutics, Inc. (RVNC) CFO Sells $297,743.88 in StockRevance Therapeutics, Inc. (RVNC) CFO Sells $297,743.88 in Stock
www.americanbankingnews.com - October 16 at 10:32 PM
Revance Therapeutics, Inc. (RVNC) Lowered to Hold at Zacks Investment ResearchRevance Therapeutics, Inc. (RVNC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 15 at 9:02 PM
ETFs with exposure to Revance Therapeutics, Inc. : October 3, 2017ETFs with exposure to Revance Therapeutics, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 11:56 AM
Revance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Buy" by BrokeragesRevance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 3 at 2:44 AM
 Brokerages Expect Revance Therapeutics, Inc. (RVNC) Will Post Quarterly Sales of $80,000.00 Brokerages Expect Revance Therapeutics, Inc. (RVNC) Will Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - October 1 at 3:16 AM
Cantor Fitzgerald Reiterates "Buy" Rating for Revance Therapeutics, Inc. (RVNC)Cantor Fitzgerald Reiterates "Buy" Rating for Revance Therapeutics, Inc. (RVNC)
www.americanbankingnews.com - September 27 at 5:32 PM
Revance Therapeutics, Inc. (RVNC) CEO Sells $179,208.00 in StockRevance Therapeutics, Inc. (RVNC) CEO Sells $179,208.00 in Stock
www.americanbankingnews.com - September 22 at 10:32 PM
Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare ConferenceRevance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference
finance.yahoo.com - September 20 at 8:34 AM
ETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017ETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017
finance.yahoo.com - September 20 at 8:34 AM
Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 7:22 AM
Cantor Fitzgerald Reaffirms Buy Rating for Revance Therapeutics, Inc. (RVNC)Cantor Fitzgerald Reaffirms Buy Rating for Revance Therapeutics, Inc. (RVNC)
www.americanbankingnews.com - September 6 at 1:28 PM
Revance Appoints Mark Foley to its Board of DirectorsRevance Appoints Mark Foley to its Board of Directors
finance.yahoo.com - September 6 at 7:51 AM
Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 1, 2017Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : September 1, 2017
finance.yahoo.com - September 2 at 8:17 AM
Revance to Participate in the 2017 Wells Fargo Securities Healthcare ConferenceRevance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
finance.yahoo.com - August 31 at 9:38 AM
Revance Therapeutics, Inc. (RVNC) CEO L Daniel Browne Sells 22,800 SharesRevance Therapeutics, Inc. (RVNC) CEO L Daniel Browne Sells 22,800 Shares
www.americanbankingnews.com - August 25 at 10:28 PM
$80,000.00 in Sales Expected for Revance Therapeutics, Inc. (RVNC) This Quarter$80,000.00 in Sales Expected for Revance Therapeutics, Inc. (RVNC) This Quarter
www.americanbankingnews.com - August 25 at 7:48 AM
JMP Securities Initiates Coverage on Revance Therapeutics, Inc. (RVNC)JMP Securities Initiates Coverage on Revance Therapeutics, Inc. (RVNC)
www.americanbankingnews.com - August 22 at 9:08 AM
Revance Therapeutics: An Undervalued Botox CompetitorRevance Therapeutics: An Undervalued Botox Competitor
seekingalpha.com - August 17 at 4:17 PM
Revance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Hold" by BrokeragesRevance Therapeutics, Inc. (RVNC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 14 at 2:44 AM
FY2017 Earnings Forecast for Revance Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:RVNC)FY2017 Earnings Forecast for Revance Therapeutics, Inc. Issued By Cantor Fitzgerald (NASDAQ:RVNC)
www.americanbankingnews.com - August 10 at 9:32 AM
Revance Therapeutics, Inc. (NASDAQ:RVNC) Posts  Earnings Results, Beats Estimates By $0.03 EPSRevance Therapeutics, Inc. (NASDAQ:RVNC) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 5 at 5:08 PM
Edited Transcript of RVNC earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of RVNC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 6:46 AM
Revance Releases Second Quarter 2017 ResultsRevance Releases Second Quarter 2017 Results
finance.yahoo.com - August 4 at 7:50 AM

Social Media

Financials

Chart

Revance Therapeutics (NASDAQ RVNC) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.